A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

NCT02055157 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Achondroplasia

Interventions

DRUG: BMN 111

Sponsor

BioMarin Pharmaceutical